Current status and progress of immunotherapy in biliary tract cancer
10.3781/j.issn.1000-7431.2023.2305-0254
- VernacularTitle:胆道恶性肿瘤免疫治疗的现状与进展
- Author:
Wei ZHANG
1
;
Bixiang ZHANG
Author Information
1. 华中科技大学同济医学院附属同济医院肝脏外科中心,湖北 武汉 430030
- Keywords:
Biliary tract cancer;
Immunotherapy;
Immune checkpoint inhibitor;
Cancer vaccines;
Adoptive cell therapy
- From:
Tumor
2023;43(6):541-551
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancer(BTC)is an aggressive cancer that arises from the epithelium of the biliary tract with high degree of malignancy,strong heterogeneity,insidious onset and poor prognosis.It has been on the rise globally in recent years,and its incidence is generally higher in Asian countries than in Western countries.Surgical resection remains the only current potentially curative treatment option for early-stage BTC.However,the surgical resection rate is low and the risk of recurrence after surgery is high.For patients with inoperable advanced or recurrent BTC,systemic chemotherapy is the preferred treatment recommendation,but treatment outcomes are still unsatisfactory.In recent years,immunotherapy has revolutionized the field of cancer treatment.Immunotherapy for advanced BTC mainly includes immune checkpoint inhibitors targeting PD-1,PD-L1 and CTLA-4,cancer vaccines and adoptive cell therapy.The review provides insights into the current status of clinical research and future research directions for immunotherapy in advanced BTC.
